SBC Medical Group Holdings Inc — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 58/100
What the filing says
SBC Medical reported Q2 2026 total revenues of $49.1M (up 13% YoY from $43.4M), net income attributable to SBC of $10.7M (up 335% YoY from $2.5M), and Adjusted EBITDA of $20.1M (up 32% YoY from $15.2M). The company added 34 clinic locations (now 287 total), grew last-twelve-month patient visits 10% to 6.9M, and increased average spend per visit 9% to $287. Management expects approximately $15M in annualized service fee increases from fee revisions for five affiliated medical corporations and expanded support for Rize Clinic and Gorilla Clinic (converted at ¥158.1/US$). Cash position stands at $184.3M.
Why this rating
Strong Q2 earnings beat (net income +335%) and growth reacceleration post-restructuring is material; $15M fee increase potential represents ~16% of quarterly revenue. However, H1 2026 EPS down 9% YoY and Adjusted EBITDA margin contracted 2pts H1 YoY, signaling mixed momentum. For a $48M market-cap company, $15M annualized opportunity is substantial but execution risk remains.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.